StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX ‚Ai Get Rating) in a report released on Friday morning. The brokerage issued a sell rating on the stock. MBRX has been the subject of a number of other research reports. Roth Capital lowered their price target on Moleculin Biotech ...

StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX ‚Ai Get Rating) in a research note released on Friday. The firm issued a sell rating on the stock. MBRX has been the topic of a number of other research reports. Oppenheimer restated an outperform rating and set a $14.00 ...

Ai Live moderated video webcast with members of management to discuss its ongoing Phase 1/2 study of core technology in development, Annamycin for the treatment of Acute Myeloid Leukemia, on Wednesday, September 28 th at 11:00 AM ET HOUSTON , Sept. 23, Moleculin Biotech, Inc. , ( Nasdaq: MBRX ) (Moleculin or the Company ...

Ai Live moderated video webcast with members of management to discuss its ongoing Phase 1/2 study of core technology in development, Annamycin for the treatment of Acute Myeloid Leukemia, on Wednesday, September 28 th at 11:00 AM ET HOUSTON , Sept. 23, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , ( Nasdaq: MBRX ) (Moleculin or ...

Equities researchers at StockNews.com initiated coverage on shares of Moleculin Biotech ( NASDAQ:MBRX ‚Ai Get Rating ) in a research report issued to clients and investors on Friday. The brokerage set a ‚Ausell‚Au rating on the stock. A number of other research analysts also recently weighed in on MBRX. Roth ...